XML 50 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
License and Collaboration Agreements - Additional Information (Detail) (USD $)
 12 Months Ended 0 Months Ended 8 Months Ended 56 Months Ended 1 Months Ended 4 Months Ended 35 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Oct. 03, 2014
Installment
Dec. 29, 2014
Dec. 31, 2010
Dec. 31, 2013
Jul. 31, 2007
May 04, 2010
May 04, 2010
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Term of license fee 10 years                  
Gain on disposition of stock $ 4,768,000aria_GainLossOnDispositionOfStock                  
License and collaboration revenue 49,688,000aria_LicenseAndCollaborationRevenue 296,000aria_LicenseAndCollaborationRevenue 514,000aria_LicenseAndCollaborationRevenue              
Service revenue 4,000aria_ServicesRevenue 27,000aria_ServicesRevenue 44,000aria_ServicesRevenue              
License agreement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payments for clinical trials 3,750,000aria_PotentialMilestonePayment
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember		                  
License agreement | Maximum                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payments 34,750,000aria_AdditionalPaymentsReceivableOnMilestoneAchievements
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		                  
Bellicum Pharmaceuticals Inc | License agreement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Amount received upon execution of the agreement       15,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember		            
License agreement, amount of agreement       50,000,000aria_ContractAmount
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember		            
Number of Installments       3aria_NumberOfInstallments
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember		            
Gain on disposition of stock       4,800,000aria_GainLossOnDispositionOfStock
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember		            
License and collaboration revenue 45,200,000aria_LicenseAndCollaborationRevenue
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember		                  
Bellicum Pharmaceuticals Inc | License agreement | due by June 30, 2015                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Installment amount       20,000,000aria_ContractInstallmentAmount
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember
/ us-gaap_StatementScenarioAxis
= aria_InstallmentOneMember		            
Bellicum Pharmaceuticals Inc | License agreement | due by June 30, 2016                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Installment amount       15,000,000aria_ContractInstallmentAmount
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember
/ us-gaap_StatementScenarioAxis
= aria_InstallmentTwoMember		            
Bellicum Pharmaceuticals Inc | License agreement | Payment One                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Proceeds from collaborators         20,000,000us-gaap_ProceedsFromCollaborators
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember
/ us-gaap_StatementScenarioAxis
= aria_PeriodicPaymentScenarioOneMember		          
Bellicum Pharmaceuticals Inc | License agreement | Payment Two                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Proceeds from collaborators         15,000,000us-gaap_ProceedsFromCollaborators
/ dei_LegalEntityAxis
= aria_BellicumPharmaceuticalsIncMember
/ us-gaap_OtherCommitmentsAxis
= aria_LicenseAgreementMember
/ us-gaap_StatementScenarioAxis
= aria_PeriodicPaymentScenarioTwoMember		          
Japan                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Refundable withholding tax 15,800,000aria_WithholdingTaxes
/ us-gaap_StatementGeographicalAxis
= country_JP		                  
License Agreement Terms                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Amount received upon execution of the agreement 77,500,000us-gaap_ProceedsFromLicenseFeesReceived
/ us-gaap_TypeOfArrangementAxis
= us-gaap_LicenseAgreementTermsMember		         50,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ us-gaap_TypeOfArrangementAxis
= us-gaap_LicenseAgreementTermsMember		        
Percentage of costs funded in the license agreement 100.00%aria_PercentageOfCostsFundedInLicenseAgreement
/ us-gaap_TypeOfArrangementAxis
= us-gaap_LicenseAgreementTermsMember		                  
License Agreement Terms | Maximum                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payments 80,000,000aria_AdditionalPaymentsReceivableOnMilestoneAchievements
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_LicenseAgreementTermsMember		                  
License Agreement Terms | Sarcoma                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Proceeds from regulatory or sales milestone payments             25,000,000aria_ProceedsFromRegulatoryOrSalesMilestonePayments
/ us-gaap_ProductOrServiceAxis
= aria_SarcomaMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_LicenseAgreementTermsMember		      
Collaborative Arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Proceeds from collaborators               $ 75,000,000us-gaap_ProceedsFromCollaborators
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember		 $ 12,800,000us-gaap_ProceedsFromCollaborators
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember		 $ 53,500,000us-gaap_ProceedsFromCollaborators
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
Percentage of global development costs funded by each party in collaboration                   50.00%aria_PercentageOfFundingByEachPartyInCollaboration
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember